Sinocare Inc.
300298.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.03B
Close$
$47.04
161.2% upside
Current Fair Value
161.2% upsideUndervalued by 161.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.03 Billion |
|---|---|
| Enterprise Value | $10.72 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.17 |
| Beta | -0.12 |
| Outstanding Shares | 532,514,321 |
Return
| Return on Equity | 8.22% |
|---|---|
| Return on Assets | 4.26% |
| Return on Invested Capital | 13.84% |
Valuation & Multiples
| P/E Ratio | 38.32 |
|---|---|
| PEG | 9.7 |
| Price to Sales | 2.0 |
| Price to Book Ratio | 3.0 |
| Enterprise Value to Revenue | 2.12 |
| Enterprise Value to EBIT | 19.82 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.14 |
| Debt to Equity | 0.47 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 23, 2026
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$1.30 B
Average shareholder expectationNext Earnings Call
Expected Date
April 16, 2027
EPS Estimate
$0.19
Average shareholder expectationRevenue Estimate
$1.26 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Sinocare Inc.
4,994 employees
CEO: Xin Yi Li Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People’s Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital ...